Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2001 2
2002 1
2003 1
2004 3
2005 4
2006 1
2007 1
2010 1
2019 3
2020 2
2021 4
2022 9
2023 7
2024 9
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Mai EK, et al. J Clin Oncol. 2025 Apr 10;43(11):1279-1288. doi: 10.1200/JCO-24-02266. Epub 2024 Dec 9. J Clin Oncol. 2025. PMID: 39652594 Free PMC article. Clinical Trial.
Fournier's gangrene.
Giagounidis AAN, Heinsch M, Kasperk R, Aul C. Giagounidis AAN, et al. Among authors: heinsch m. Ann Hematol. 2003 Aug;82(8):531-532. doi: 10.1007/s00277-003-0688-z. Epub 2003 Jun 14. Ann Hematol. 2003. PMID: 12811517 No abstract available.
Acute basophilic leukemia.
Giagounidis AA, Hildebrandt B, Heinsch M, Germing U, Aivado M, Aul C. Giagounidis AA, et al. Among authors: heinsch m. Eur J Haematol. 2001 Aug;67(2):72-6. doi: 10.1034/j.1600-0609.2001.t01-1-00487.x. Eur J Haematol. 2001. PMID: 11722593
Mental health care needs in cystic fibrosis: A scoping review.
Tickner C, Holland L, Wark P, Hilton J, Morrison C, Kay-Lambkin F, Heinsch M. Tickner C, et al. Among authors: heinsch m. Soc Work Health Care. 2022 Apr 14:1-15. doi: 10.1080/00981389.2022.2060422. Online ahead of print. Soc Work Health Care. 2022. PMID: 35422201 Review.
The Triple E project: a factorial randomised controlled trial to enhance engagement with eHealth approaches to improve health risk behaviours among adolescents.
Thornton L, Corliss C, Deen H, Teesson M, Champion KE, Partridge SR, Heinsch M, Spring B, Gardner LA, Rickwood D, Sunderland M, Newton NC, Zaman S, Redfern J, Osman B, Wilson J, Watt M, Kay-Lambkin F. Thornton L, et al. Among authors: heinsch m. BMC Public Health. 2024 Oct 3;24(1):2697. doi: 10.1186/s12889-024-20124-5. BMC Public Health. 2024. PMID: 39363157 Free PMC article.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel KC, Raab MS, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators. Mai EK, et al. Lancet Haematol. 2024 Feb;11(2):e101-e113. doi: 10.1016/S2352-3026(23)00366-6. Lancet Haematol. 2024. PMID: 38302221 Free article. Clinical Trial.
45 results